Anavex Life Sciences (STU:12X1) FCF Margin % : 0.00% (As of Dec. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Anavex Life Sciences FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Anavex Life Sciences's Free Cash Flow for the three months ended in Dec. 2024 was €-11.58 Mil. Anavex Life Sciences's Revenue for the three months ended in Dec. 2024 was €0.00 Mil. Therefore, Anavex Life Sciences's FCF Margin % for the quarter that ended in Dec. 2024 was 0.00%.

As of today, Anavex Life Sciences's current FCF Yield % is -4.28%.

The historical rank and industry rank for Anavex Life Sciences's FCF Margin % or its related term are showing as below:

STU:12X1's FCF Margin % is not ranked ^*
in the Biotechnology industry.
Industry Median: -127.22
* Ranked among companies with meaningful FCF Margin % only.

Anavex Life Sciences FCF Margin % Historical Data

The historical data trend for Anavex Life Sciences's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Anavex Life Sciences FCF Margin % Chart

Anavex Life Sciences Annual Data

Trend

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Sep24

FCF Margin %

Get a 7-Day Free Trial

Anavex Life Sciences Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
FCF Margin %	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Anavex Life Sciences's FCF Margin %

For the Biotechnology subindustry, Anavex Life Sciences's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Anavex Life Sciences's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Anavex Life Sciences's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Anavex Life Sciences's FCF Margin % falls into.

Save Embed

;

Save Embed

;

Anavex Life Sciences FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Anavex Life Sciences's FCF Margin for the fiscal year that ended in Sep. 2024 is calculated as

FCF Margin	=	Free Cash Flow (A: Sep. 2024 )	/	Revenue (A: Sep. 2024 )
	=	-27.762	/	0
	=	%

Anavex Life Sciences's FCF Margin for the quarter that ended in Dec. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2024 )	/	Revenue (Q: Dec. 2024 )
	=	-11.575	/	0
	=	%

Anavex Life Sciences FCF Margin % Related Terms

Thank you for viewing the detailed overview of Anavex Life Sciences's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Anavex Life Sciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Anavex Life Sciences Corp (STU:12X1) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

AVXL:USA 0HFR:UK 12X1:Germany

Address

630 5th Avenue, 20th Floor, New York, NY, USA, 10111

Website

https://www.anavex.com

Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are further used in the analysis of clinical trials. The company's focus is on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its various therapeutic candidates in different stages of development include Anavex 2-73 (Blacamesine), Anavex 3-71 (AF710B), Anavex 1-41, and Anavex 1066.

Anavex Life Sciences Headlines

No Headlines